Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study)

被引：0

作者：

Iwuji, Collins ^{[1
,2
]}

Waters, Laura ^{[3
]}

Milinkovic, Ana ^{[4
]}

Orkin, Chloe ^{[5
,6
]}

Fox, Julie ^{[7
]}

Post, Frank ^{[8
]}

Perry, Nicky ^{[9
]}

Bruce, Chloe ^{[10
]}

Dailey, Natalie ^{[10
]}

To, Ye ^{[10
]}

Bremner, Stephen ^{[10
,11
]}

Churchill, Duncan ^{[9
]}

Geretti, Anna Maria ^{[12
,13
,14
]}

机构：

[1] Univ Sussex, Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton BN1 9PX, England

[2] Africa Hlth Res Inst, Kwa Zulu, South Africa

[3] Cent & Northwest London NHS Fdn Trust, Mortimer Market Ctr, London, England

[4] Chelsea & Westminster Hosp NHS Fdn Trust, London, England

[5] Queen Mary Univ London, Blizard Inst, Fac Med & Dent, London, England

[6] Barts Hlth NHS Trust, London, England

[7] Guys & St ThomasNHS Fdn Trust, London, England

[8] Kings Coll Hosp NHS Fdn Trust, London, England

[9] Univ Hosp Sussex NHS Fdn Trust, London, England

[10] Univ Sussex, Brighton & Sussex Clin Trials Unit, Brighton, England

[11] Univ Sussex, Brighton & Sussex Med Sch, Dept Primary Care & Publ Hlth, Brighton, England

[12] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy

[13] Royal Free London NHS Fdn Trust North Mid, London, England

[14] Kings Coll London, Sch Immun & Microbial Sci, London, England

来源：

VIROLOGY JOURNAL | 2025年 / 22卷 / 01期

关键词：

HIV; Drug resistance; Archive; Bictegravir; Tenofovir alafenamide; Integrase strand transfer inhibitor; Boosted protease inhibitor; Switch; TENOFOVIR DISOPROXIL FUMARATE; NON-INFERIORITY; CARDIOVASCULAR-DISEASE; HIV-1; INFECTION; DOUBLE-BLIND; MULTICENTER; DOLUTEGRAVIR; K65R; EMTRICITABINE; LAMIVUDINE;

D O I：

10.1186/s12985-025-02648-3

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

BackgroundThere are limited data on how historical nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs) other than M184V/I, affect the activity of B/F/TAF. We evaluated the outcomes of switching virologically suppressed (HIV-1 RNA < 50 copies/mL) individuals harbouring major RAMs from boosted protease inhibitor (bPI)-based therapy to B/F/TAF. MethodsParticipants had various historical genotypic patterns including M184V/I, <= 2 thymidine analogue mutations (TAMs), and other NRTI RAMs (NAMs), and no integrase resistance. Baseline RAMs were explored by retrospective sequencing of cellular HIV-1 DNA. Participants were randomised (1:1) to switching to B/F/TAF either immediately or after 24 weeks. The primary outcome was the proportion of participants maintaining virological suppression (pure virologic response) at week-24; secondary outcomes were proportion of participants with virological suppression at week-48, pre-specified safety measures, and treatment-emergent resistance. ResultsHistorically, 21/72 (29.2%) participants had M184V/I, 5 (6.9%) M184V/I + 1 NAM, 31 (43.1%) 1 TAM +/- M184V/I +/- 1 NAM, and 15 (20.8%) 2 TAMs +/- M184V/I +/- 1 NAM. At week-24, proportions maintaining virological suppression were 33/33 (100%) on B/F/TAF vs. 38/39 (97.4%) on bPI (difference 2.6%; 95% CI -2.4%, 7.5%). Drug-related adverse events (AEs) were reported in 10/33 (30.3%) vs. 1/39 (2.6%), respectively. The immediate switch arm had improved lipid parameters but increased HbA1c and weight. Virological suppression was maintained at week-48. There were six discontinuations; four on B/F/TAF were drug-related and the two on bPI were not drug-related. ConclusionsHistorical NRTI resistance did not compromise the effectiveness of B/F/TAF in virologically suppressed adults. 12% experienced treatment-limiting AEs after switching. RegistrationEudraCT no: 2018-004732-30

引用

页数：11

共 11 条

[1] A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naive, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Iwuji, Collins C.
Churchill, Duncan
Bremner, Stephen
Perry, Nicky
To, Ye
Lambert, Debbie
Bruce, Chloe
Waters, Laura
Orkin, Chloe
Geretti, Anna Maria
BMC INFECTIOUS DISEASES, 2020, 20 (01)
[2] Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
Kityo, Cissy
Hagins, Debbie
Koenig, Ellen
Avihingsanon, Anchalee
Chetchotisakd, Ploenchan
Supparatpinyo, Khuanchai
Gankina, Natalya
Pokrovsky, Vadim
Voronin, Evgeny
Stephens, Jeffrey L.
DeJesus, Edwin
Wang, Hui
Acosta, Rima K.
Cao, Huyen
Quirk, Erin
Martin, Hal
Makadzange, Tariro
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (03) : 321 - 328
[3] A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Collins C. Iwuji
Duncan Churchill
Stephen Bremner
Nicky Perry
Ye To
Debbie Lambert
Chloe Bruce
Laura Waters
Chloe Orkin
Anna Maria Geretti
BMC Infectious Diseases, 20
[4] Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Daar, Eric S.
Dejesus, Edwin
Ruane, Peter
Crofoot, Gordon
Oguchi, Godson
Creticos, Catherine
Rockstroh, Juergen K.
Molina, Jean-Michel
Koenig, Ellen
Liu, Ya-Pei
Custodio, Joseph
Andreatta, Kristen
Graham, Hiba
Cheng, Andrew
Martin, Hal
Quirk, Erin
LANCET HIV, 2018, 5 (07): : E347 - E356
[5] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Mills, Anthony
Arribas, Jose R.
Andrade-Villanueva, Jaime
DiPerri, Giovanni
Van Lunzen, Jan
Koenig, Ellen
Elion, Richard
Cavassini, Matthias
Madruga, Jose Valdez
Brunetta, Jason
Shamblaw, David
DeJesus, Edwin
Orkin, Chloe
Wohl, David A.
Brar, Indira
Stephens, Jeffrey L.
Girard, Pierre-Marie
Huhn, Gregory
Plummer, Andrew
Liu, Ya-Pei
Cheng, Andrew K.
McCallister, Scott
LANCET INFECTIOUS DISEASES, 2016, 16 (01) : 43 - 52
[6] Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Ramgopal, Moti N.
Castagna, Antonella
Cazanave, Charles
Diaz-Brito, Vicens
Dretler, Robin
Oka, Shinichi
Osiyemi, Olayemi
Walmsley, Sharon
Sims, James
Di Perri, Giovanni
Sutton, Kenneth
Sutherland-Phillips, Denise
Berni, Alessandro
Latham, Christine L.
Zhang, Feifan
D'Amico, Ronald
Bernaldez, Miguel Pascual
Van Solingen-Ristea, Rodica
Van Eygen, Veerle
Patel, Parul
Chounta, Vasiliki
Spreen, William R.
Garges, Harmony P.
Smith, Kimberly
van Wyk, Jean
LANCET HIV, 2023, 10 (09): : E566 - E577
[7] Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
Janssen, Harry L. A.
Lim, Young-Suk
Lampertico, Pietro
Heo, Jeong
Chen, Chi-Yi
Fournier, Claire
Tsang, Tak Yin Owen
Bae, Ho
Chen, Chien-Hung
Coffin, Carla S.
Ahn, Sang Hoon
Trinh, Huy
Flaherty, John F.
Abramov, Frida
Zhao, Yang
Liu, Yang
Lau, Audrey
German, Polina
Chuang, Wan-Long
Agarwal, Kosh
Gane, Edward
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (08): : 718 - 733
[8] Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
Pozniak, Anton
Markowitz, Martin
Mills, Anthony
Stellbrink, Hans-Juergen
Antela, Antonio
Domingo, Pere
Girard, Pierre-Marie
Henry, Keith
Thai Nguyen
Piontkowsky, David
Garner, Will
White, Kirsten
Guyer, Bill
LANCET INFECTIOUS DISEASES, 2014, 14 (07) : 590 - 599
[9] Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
Arribas, Jose R.
Pialoux, Gilles
Gathe, Joseph
Di Perri, Giovanni
Reynes, Jacques
Tebas, Pablo
Thai Nguyen
Ebrahimi, Ramin
White, Kirsten
Piontkowsky, David
LANCET INFECTIOUS DISEASES, 2014, 14 (07) : 581 - 589
[10] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Maggiolo, Franco
Rizzardini, Giuliano
Raffi, Francois
Pulido, Federico
Gracia Mateo-Garcia, Maria
Molina, Jean-Michel
Ong, Edmund
Shao, Yongwu
Piontkowsky, David
Das, Moupali
McNicholl, Ian
Haubrich, Richard
LANCET HIV, 2019, 6 (10): : E655 - E666

← 1 2 →